StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Stock analysts at StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report released on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

Cyclacel Pharmaceuticals stock opened at $0.23 on Wednesday. The stock has a market capitalization of $46.88 million, a P/E ratio of -0.02 and a beta of 0.15. Cyclacel Pharmaceuticals has a 12-month low of $0.17 and a 12-month high of $4.00. The firm’s 50-day moving average is $0.29 and its two-hundred day moving average is $0.43.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings data on Wednesday, April 2nd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Insider Activity at Cyclacel Pharmaceuticals

In related news, CEO David E. Lazar sold 194,628,820 shares of the business’s stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 68.00% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.